1. Home
  2. OKLO vs ZYME Comparison

OKLO vs ZYME Comparison

Compare OKLO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OKLO
  • ZYME
  • Stock Information
  • Founded
  • OKLO 2013
  • ZYME 2003
  • Country
  • OKLO United States
  • ZYME United States
  • Employees
  • OKLO N/A
  • ZYME N/A
  • Industry
  • OKLO
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • OKLO
  • ZYME Health Care
  • Exchange
  • OKLO NYSE
  • ZYME Nasdaq
  • Market Cap
  • OKLO 710.6M
  • ZYME 751.6M
  • IPO Year
  • OKLO N/A
  • ZYME 2017
  • Fundamental
  • Price
  • OKLO $19.48
  • ZYME $13.05
  • Analyst Decision
  • OKLO Buy
  • ZYME Buy
  • Analyst Count
  • OKLO 2
  • ZYME 6
  • Target Price
  • OKLO $10.00
  • ZYME $18.83
  • AVG Volume (30 Days)
  • OKLO 11.1M
  • ZYME 416.1K
  • Earning Date
  • OKLO 02-13-2025
  • ZYME 10-31-2024
  • Dividend Yield
  • OKLO N/A
  • ZYME N/A
  • EPS Growth
  • OKLO N/A
  • ZYME N/A
  • EPS
  • OKLO N/A
  • ZYME N/A
  • Revenue
  • OKLO N/A
  • ZYME $62,199,000.00
  • Revenue This Year
  • OKLO N/A
  • ZYME $21.53
  • Revenue Next Year
  • OKLO N/A
  • ZYME N/A
  • P/E Ratio
  • OKLO N/A
  • ZYME N/A
  • Revenue Growth
  • OKLO N/A
  • ZYME N/A
  • 52 Week Low
  • OKLO $5.35
  • ZYME $7.97
  • 52 Week High
  • OKLO $28.12
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • OKLO 56.51
  • ZYME 42.19
  • Support Level
  • OKLO $17.14
  • ZYME $12.43
  • Resistance Level
  • OKLO $20.29
  • ZYME $14.10
  • Average True Range (ATR)
  • OKLO 1.84
  • ZYME 0.63
  • MACD
  • OKLO -0.18
  • ZYME -0.10
  • Stochastic Oscillator
  • OKLO 75.48
  • ZYME 26.50

About OKLO OKLO INC

Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: